*Press release*

# Sensorion announces the registration of its *document de base* with the *Autorité des Marchés Financiers* (AMF) within the framework of its planned IPO on the Alternext Paris

**Montpellier, March 13, 2015 – Sensorion, a biotech specialising in the treatment of inner ear diseases, today announces the registration of its *document de base* with the *Autorité des Marchés Financiers* (AMF), the French stock market authority, under number I.15-011 on March 12, 2015, within the framework of its project to list its shares on the Alternext Paris market[1].**

Founded in 2009 and located in Montpellier, in the south of France, Sensorion targets all severe inner ear disorders by treating both symptoms and progressive lesions, and is developing three drug candidate programmes to provide a response to currently-unmet medical needs.

## A unique technological platform in inner ear diseases

Sensorion has developed unique scientific expertise in neurosensory cells, which are crucial for the inner ear to operate correctly. Dysfunctions of the neurosensory cells are the cause of highly-debilitating symptoms such as severe vertigo or tinnitus, and lesions that can result in a loss of hearing and balance function.

Within this framework, Sensorion has thus perfected a comprehensive technological platform enabling it to rapidly identify and test the best drug candidates to treat all inner ear disorders, both symptomatic and anti-lesional. This platform, which is protected by a portfolio of 7 patent families, is the focus of growing interest from major pharmaceutical laboratories.

## A portfolio covering all types of severe inner ear pathologies

Providing a response to real medical needs, the drug candidates chosen by Sensorion cover all severe inner ear pathologies.

The first two drug candidates are currently in or about to enter the clinical trial phase:

- SENS-111, at the start of the 1b clinical phase, aimed at treating severe vertigo crisis;
- SENS-218, which should enter the 1b clinical phase in early 2016, aimed at preventing and treating medium and long-term complications associated with progressive lesions of the inner ear.

A third programme, SENS-300, aimed at protecting the inner ear from the toxicity of certain drugs, notably within the framework of chemotherapy, and thus preventing balance disorders and loss of hearing. This programme is in the final phase for selecting the drug candidate that could enter the 1b clinical phase in 2016.

## A strategy to rapidly access an unmet market worth over 10 billion dollars[2]

Sensorion is aiming to become a major player in the treatment of inner ear pathologies, a large emerging market whose worldwide potential is estimated at over 10 billion dollars. Sensorion targets sizeable unmet medical needs, as no drug currently provides an efficient solution to these highly-debilitating pathologies that affect more than 140 million patients worldwide. Its strategy consists in rapidly developing a diverse portfolio of products that meet this major need thanks to:

- a reduction in development time and risks by choosing known molecules that have already completed critical pharmaceutical development stages;
- a choice of easy-to-administer treatments, notably tablets or capsules taken orally, and non-invasive treatments in order to easily treat the greatest possible number of patients.

[1] Subject to AMF approval and market conditions
[2] Source: Alcimed, Sensorion

## An experienced team to accelerate the clinical programme and ensure Sensorion's long-term development

Laurent Nguyen, CEO, is a doctor of medicine with over 20 years of experience with major pharmaceutical laboratories (Roche, P. Fabre, Merck, etc.), notably in Marketing, Business Development and Licensing. With substantial knowledge of market access and sales, he has put together a team of experts who are recognised in the pharmaceutical industry to work on the Sensorion project:

- Pierre Attali, Chief Medical Officer, is a doctor of medicine with over 30 years of experience in international pharmaceutical laboratories and biotechnology companies. During his career, he has registered more than 10 new products or formulations in Europe, the United States and Asia, some of which have opened up entirely new therapeutic areas. He has contributed to the publication of more than 100 peer-reviewed articles, conference presentations and patents. His medical and R&D expertise will support the development of Sensorion's drugs.
- Patrick Langlois, appointed Chairman of the Board, can provide Sensorion with his support and strategic advice thanks to his financial expertise and his recognized experience acquired through 40 years with major industrial companies (Vice-Chairman of the Board at Aventis) and financial institutions (Senior Advisor at JP Morgan), and from his involvement in the governance of a number of biotech companies in France and abroad.

▪▪▪

The registration of the *document de base* is the first step towards Sensorion's planned Initial Public Offering on the Alternext market in Paris, which should take place in 2015 subject to market conditions and to the AMF's granting of approval for the prospectus relative to the operation.

**Availability of the *document de base* –** Sensorion's *document de base* registered with the AMF on March 12, 2015 under reference number I.15-011 is available free of charge on request from Sensorion (Le Bruyère 2000 - Bat 2 - Zone le Millénaire - 650 rue Henri Becquerel - 34000 Montpellier, France), as well as on the Sensorion website (www.sensorion-pharma.com) and AMF website (www.amf-france.org).

**Risk factors -** Sensorion would like to draw your attention to Chapter 4, "Risk Factors", of the *document de base* registered with the AMF.

## About Sensorion

Spun off from Inserm (the French institute of health and medical research) in 2009, Sensorion is a biotech that specialises in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. Backed by its pharmaceutical R&D experience and a comprehensive technological platform, Sensorion is developing three major research programmes for treating symptoms during acute vertigo crisis or tinnitus and for preventing progressive lesions and chemotherapy toxicity in the inner ear. Based in Montpellier, southern France, within the university and hospital hub, Sensorion has a portfolio of 7 patent families, has 15 employees and receives financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.
www.sensorion-pharma.com

## Contacts

**Sensorion**
Laurent Nguyen
CEO
contact@sensorion-pharma.com
Tel: +33 (0)4 67 20 77 30

**NewCap**
Dusan Oresansky / Antoine Denry
Investor Relations & Strategic Communications
sensorion@newcap.fr
Tel: +33 (0)1 44 71 94 92

## Disclaimer

of the prospectus. It consists of the Document de Base, which is the subject of this report, and the offering circular that will be submitted to the AMF at a later date.

In particular, this document does not constitute an offer for the sale or the subscription of Sensorion shares in the United States. These marketable securities cannot be offered or sold in the United States without a registration or an exemption from registration under the US Securities Act of 1933, amended (the "US Securities Act), with the specification that Sensorion's marketable securities have not been, and will not be, registered under the US Securities Act and that Sensorion has no intention of proceeding with a public offering of marketable securities in the United States.

For the Member States of the European Economic Area who have implemented the Prospectus Directive (each being known as a "Relevant Member State"), no action has been taken, or will be taken, to facilitate a public offering of securities requiring the publication of a prospectus in any of the Relevant Member States, other than France. Consequently, any new or existing shares offering by Sensorion can only be achieved in any of the Relevant Member States, other than France, for the benefit of (i) legal entities that are qualified investors as defined by the Prospectus Directive, (ii) of less than 150 natural persons or legal entities (other than qualified investors as defined by the Prospectus Directive), as permitted by the Prospectus Directive; or, under any scenario exempting the Company from publishing a prospectus in accordance with Article 3(2) of the Prospectus Directive and/or regulations applicable in the Relevant Member State, provided that such a new or existing shares offering by the Company does not generate a new obligation for the Company to publish a prospectus in application of Article 3 of the Prospectus Directive or a supplement to the prospectus in accordance with Article 16 of the Prospectus Directive. For the purposes of this paragraph, the expression, "public offering" of new or existing shares of the Company in any Relevant Member State means any communication addressed to persons, in any form and by any means, and providing sufficient information as to the terms and conditions of the offering of new or existing share of the Company, to enable an investor to decide to subscribe to, or purchase these new or existing shares of the Company, in the manner in which this definition was, if applicable, modified within the Member State in question by any measure intended to implement the Prospectus Directive in this particular Member State.

In the United Kingdom, this document does not constitute an approved prospectus as defined by Article 85 of the Financial Services and Markets Act 2000, amended (the "FSMA"). It has not been prepared in accordance with Prospectus Rules issued by the UK Financial Services Authority (the "FSA") in application of Article 73A of the FSMA and has not been approved or filed with the FSA or any other competent authority under the requirements of the Prospectus Directive. The new or existing shares of the Company cannot be offered or sold to the public in the United Kingdom (as defined by Articles 85 and 102B of FSMA), except under a scenario in which it would be in compliance with the law to do so without making an approved prospectus available to the public (as defined by Article 85 of FSMA) prior to the offering taking place. This document is solely intended for individuals who (i) have the professional investment experience mentioned in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are mentioned in Article 49 (2)(a) in (d)("high net worth bodies corporate, unincorporated associations etc") of Financial Promotion Order, (iii) are physically outside the United Kingdom, or (iv) to whom an invitation or incentive to engage in an investment activity (as defined by Article 21 of the FSMA) regarding the issuance or the sale of securities may be legally communicated by a person other than the authorised individual, as defined by Article 31 of the FSMA, and, when the contents of the communication in question has not been approved as required by Article 21 of the FSMA, by such an authorised person (all persons being known aggregately as the "Qualified Person"). This document is solely intended for Qualified Persons and must not be used by persons who are not Qualified Persons. Any investment or investment activity to which this document refers is accessible only to Qualified Persons and can only be offered or concluded with Qualified Persons.

This document contains statements of expected outcomes. No guarantee can be given as to the fulfilment of these expected outcomes, which are subject to risks such as, in particular, those described in Chapter 4 of the Document de Base referenced in this report.

***This document may not be published, disseminated or distributed, directly or indirectly, in the United States, Canada, Australia, and Japan.***